TransMedics Group Inc. (TMDX)
TransMedics Group, Inc. (TMDX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
TransMedics Group, Inc. (TMDX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Here's Why TransMedics (TMDX) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
TransMedics Group: I Estimate A Large Upside By The End Of 2028
TransMedics is reaffirmed as a buy, with significant upside potential based on improved margins and slower share dilution. I estimate 2028 revenue at $1.35 billion, driven by achieving 10k transplants at a $105,000 average price, plus $300 million in additional revenue. Net income margin is now forecast at 17.5% for 2028, with long-term potential to exceed 20%, as seen in peer medical device companies.
Reasons to Retain TransMedics Stock in Your Portfolio for Now
TMDX gains momentum as OCS technology, a robust pipeline and strong Q3 results fuel growth, though gross margin pressure tempers the outlook.
Why TransMedics (TMDX) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
TransMedics (TMDX) Crossed Above the 50-Day Moving Average: What That Means for Investors
TransMedics (TMDX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, TMDX broke through the 50-day moving average, which suggests a short-term bullish trend.
TransMedics (TMDX) Just Overtook the 20-Day Moving Average
From a technical perspective, TransMedics (TMDX) is looking like an interesting pick, as it just reached a key level of support. TMDX recently overtook the 20-day moving average, and this suggests a short-term bullish trend.
TransMedics (TMDX) is a Top-Ranked Growth Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
TransMedics: Growth Tailwinds Should Provide Upside In 2026
TransMedics delivered solid year-over-year growth in Q3, despite seasonal weakness and concerns over U.S. liver market saturation. The next-gen heart and lung trials, along with an increased focus on international expansion, will be supportive of growth going forward. While TransMedics faces margin headwinds in the short term, profitability continues to improve and will be supportive of the company's valuation in the long term.
TMDX Stock Falls Despite Q3 Earnings Beat Estimates, Revenues Up Y/Y
TransMedics posts surging profit and higher revenues on strong OCS and logistics growth, yet its shares slide despite upbeat Q3 results.
TransMedics: Q3 Results Disappointed, As Expected (Rating Upgrade)
TransMedics shares dropped after Q3 results beat consensus but missed high investor expectations, creating a favorable entry point. Q3 is seasonally weak for TMDX, but the current selloff makes valuation attractive and expectations more reasonable. Industry data signals a strong Q4 ahead, supporting the case for near-term upside in TMDX.
TransMedics Group, Inc. (TMDX) Q3 2025 Earnings Call Transcript
TransMedics Group, Inc. ( TMDX ) Q3 2025 Earnings Call October 29, 2025 4:30 PM EDT Company Participants Waleed Hassanein - Founder, President, CEO & Director Gerardo Hernandez - CFO & Treasurer Conference Call Participants Dorothy Morgan - Gilmartin Group LLC K. Gong - JPMorgan Chase & Co, Research Division William Plovanic - Canaccord Genuity Corp., Research Division Matthew Mardula - William Blair & Company L.L.C.
